Rocket Lab: Iridium Could Explode EBITDA, But A Wildcard Decides If It's Worth It

Rocket Lab canceled its $3.6 billion bridge loan without drawing on it, and the Iridium deal is now fully funded. Iridium contributes roughly $500 million in annual EBITDA, which the article says would move Rocket Lab from an $80 million EBITDA loss to about $420 million before Neutron. Up to 72 million new shares are expected, with 17 million tied to the collar’s stock-price window.

Analysis

The strategic shift is less about adding EBITDA than changing RKLB’s investor profile: recurring communications cash flow could help fund launch and Neutron investment, but the combined company will also be judged on satellite replacement capex, integration, and the cost and terms of its actual funding. EBITDA is not free cash flow; the headline contribution does not establish debt-service capacity or how much cash remains for growth investment.

Near term, expected share issuance can act as an overhang even if the transaction is funded, while uncertainty about the collar may add volatility around its price window. Over 1–3 months, the key checks are closing conditions, definitive financing sources and costs, the final share count, and pro forma cash flow after capex and interest. Over 6–18 months, execution and capital allocation determine whether IRDM’s cash generation supports RKLB’s investment cycle or is absorbed by network upkeep and integration.

Contrarian point: the market may treat the EBITDA addition as immediate de-risking, when the acquired cash flow may be less discretionary than headline EBITDA implies. Conversely, if funding avoids costly borrowing and dilution is below the maximum, investors may overprice the issuance overhang. The thesis weakens if closing slips, funding costs rise, or pro forma free cash flow disappoints.

Key Decisions for Investors

• Do not trade the EBITDA headline alone. Put RKLB on an event watchlist pending confirmation of funding sources, borrowing costs, closing conditions, and pro forma free cash flow after satellite capex and interest.
• Treat the stated maximum share issuance as a potential supply overhang, not a confirmed dilution outcome. Verify the consideration mechanics and collar thresholds before taking a directional position; the contingent portion could affect timing and volatility.
• If the stock reacts sharply to the financing announcement, consider waiting for transaction documents and the next guidance update rather than chasing. A sustained rally without quantified cash-flow and funding detail is vulnerable to reversal.
• Falsify the positive funding thesis if the transaction is delayed, financing is materially more expensive than expected, or management’s post-close outlook shows cash generation being consumed by capex, interest, or integration.